<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01311765</url>
  </required_header>
  <id_info>
    <org_study_id>P081248</org_study_id>
    <nct_id>NCT01311765</nct_id>
  </id_info>
  <brief_title>Duration of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in ICU</brief_title>
  <acronym>DURAPOP</acronym>
  <official_title>Comparison of Two Durations of Antibiotic Therapy in the Treatment of Severe Postoperative Peritonitis Admitted in Intensive Care Unit: a Randomised Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators purpose is to demonstrate that a short antibiotic therapy (8 days) for&#xD;
      postoperative peritonitis brings an increased number of antibiotic-free days over a 28 days&#xD;
      period when compared to conventional (15 days) treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective randomized study involving 25 centers. Our goal is to demonstrate in&#xD;
      the course of postoperative peritonitis that a short antibiotic therapy (8 days) compared to&#xD;
      conventional antibiotic treatment (15 days) decreases the duration of exposure to antibiotics&#xD;
      over a 28 days period . Patients admitted in ICU, operated for postoperative peritonitis and&#xD;
      receiving an adequate antibiotic therapy will be identified and after informed consent is&#xD;
      obtained will be randomized to receive a short course of antibiotic therapy (8 days) or a&#xD;
      long course of antibiotic therapy (15 days). The primary endpoint is the number of&#xD;
      antibiotic-free days at D28 after inclusion (analysis of superiority) . Secondary endpoints&#xD;
      include mortality at D45 after inclusion (analysis of equivalence), the occurrence of relapse&#xD;
      of infection, success rate of clinically and microbiologically evaluable patients, and&#xD;
      emergence of multidrug resistant microorganisms in clinical isolates or hygiene samples.&#xD;
      Patient data through day 45 following the initial intervention or until hospital discharge&#xD;
      will be tracked.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number of antibiotic-free days at D28 after inclusion</measure>
    <time_frame>28 days</time_frame>
    <description>The number of antibiotic-free days at D28 after inclusion (analysis of superiority)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at D45 after inclusion</measure>
    <time_frame>45 days</time_frame>
    <description>Mortality at D45 after inclusion (analysis of equivalence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of ICU and hospital stay</measure>
    <time_frame>45 days</time_frame>
    <description>Duration of ICU and hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in SOFA score</measure>
    <time_frame>8 days</time_frame>
    <description>Changes in SOFA score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive without organ failure</measure>
    <time_frame>28 days</time_frame>
    <description>Number of days alive without organ failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure rate for clinically evaluable patients</measure>
    <time_frame>28 days</time_frame>
    <description>Failure rate for clinically evaluable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failure rate for microbiologically evaluable patients</measure>
    <time_frame>28 days</time_frame>
    <description>Failure rate for microbiologically evaluable patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of relapse within 45 days</measure>
    <time_frame>45 days</time_frame>
    <description>Rate of relapse within 45 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Emergence of multidrug resistant microorganisms in clinical isolates and hygiene samples</measure>
    <time_frame>ICU discharge</time_frame>
    <description>Emergence of multidrug resistant microorganisms in clinical isolates and hygiene samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of antibiotic agents</measure>
    <time_frame>28 days</time_frame>
    <description>Total cost of antibiotic agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of procalcitonin plasma concentration</measure>
    <time_frame>15 days</time_frame>
    <description>Evolution of procalcitonin plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death within 45 days in specific subpopulations (elderly patients &gt;80 years ; morbidly obese patients BMI&gt;25kg/m2 ; severe infection with SAPSII score &gt;40 ;peritoneal infection involving pseudomonas or enterococci ; bacteriemic infections)</measure>
    <time_frame>45 days</time_frame>
    <description>Rate of death within 45 days in specific subpopulations (elderly patients &gt;80 years ; morbidly obese patients BMI&gt;25kg/m2 ; severe infection with SAPSII score &gt;40 ;peritoneal infection involving pseudomonas or enterococci ; bacteriemic infections)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cost of hospital stay and evaluation of costs and resources impact for the hospital administration</measure>
    <time_frame>Hospital discharge</time_frame>
    <description>Total cost of hospital stay and evaluation of costs and resources impact for the hospital administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">244</enrollment>
  <condition>Postoperative Peritonitis</condition>
  <arm_group>
    <arm_group_label>8 day-antibiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Duration of antibiotic therapy limited to 8 days: Antibiotics received for up to 8 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 day-antibiotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Antibiotics received for up to15 days following surgery for postoperative peritonitis in patients hospitalised in intensive care unit corresponding to usual practice and recommendations</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Duration of antibiotic therapy limited to 8 days</intervention_name>
    <description>Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment</description>
    <arm_group_label>8 day-antibiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The eligible patients have to fulfill all the following criteria&#xD;
&#xD;
          1. patients admitted in intensive care unit&#xD;
&#xD;
          2. in the 24 hours following surgery for postoperative intra-abdominal infection (defined&#xD;
             as gross pus or purulent effusion within the peritoneal cavity or in one or several&#xD;
             collections). Postoperative infection will be defined as an infection observed in a&#xD;
             delay of 60 days following a procedure (endoscopy, surgery (abdominal, urologic,&#xD;
             gynecologic or vascular surgery or any surgery performed in the peritoneal or&#xD;
             retroperitoneal space) or interventional radiology)&#xD;
&#xD;
          3. having peroperative microbiologic samples collected&#xD;
&#xD;
          4. receiving an empiric antibiotic therapy initiated within the first 24 hours after&#xD;
             completion of surgery&#xD;
&#xD;
          5. with a written informed consent from the patient or the relative or the legal&#xD;
             representative or with an emergency consent&#xD;
&#xD;
        Non-inclusion criteria :&#xD;
&#xD;
        Patients with one of the following criteria are eligible for the study :&#xD;
&#xD;
          1. age&lt;18&#xD;
&#xD;
          2. pregnancy&#xD;
&#xD;
          3. Duration of stay following inclusion &lt;72 hours&#xD;
&#xD;
          4. neutropenia (PMN&lt;500/mm3) due to chemotherapy or hematological disease&#xD;
&#xD;
          5. AIDS stage C&#xD;
&#xD;
          6. Immunosuppressive therapy or prolonged steroid therapy (≥0.5 mg/kg/d of prednisone or&#xD;
             equivalent &gt;1 month&#xD;
&#xD;
          7. Bowel perforation following endoscopy treated in a delay &lt;6 hours after injury&#xD;
&#xD;
          8. Uterine perforation following a surgical procedure treated in a delay &lt;6 hours after&#xD;
             injury&#xD;
&#xD;
          9. Moribund patient (SAPS II score &gt;65 within 12 hours preceding inclusion)&#xD;
&#xD;
         10. Limitation of treatment previously decided&#xD;
&#xD;
         11. Surgery considered as non curative by the surgeon&#xD;
&#xD;
         12. Patient included in another clinical trial evaluating an antimicrobial agent&#xD;
&#xD;
        Secondary exclusion criteria:&#xD;
&#xD;
        Among the eligible patients, those who have one of the following criteria will be excluded&#xD;
&#xD;
          1. Negative culture of the peritoneal fluid&#xD;
&#xD;
          2. Peritoneal culture exclusively fungal&#xD;
&#xD;
          3. Inadequate empiric antibiotic therapy (not targeting all the microorganisms cultured&#xD;
             from peritoneal or blood cultures) within 24 hours after surgery&#xD;
&#xD;
          4. Death between D1 and D8&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe Montravers, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>February 22, 2011</study_first_submitted>
  <study_first_submitted_qc>March 8, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2011</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Postoperative peritonitis</keyword>
  <keyword>Intra-abdominal infection</keyword>
  <keyword>Surgery</keyword>
  <keyword>Laparotomy</keyword>
  <keyword>Nosocomial infection</keyword>
  <keyword>Antibiotic therapy</keyword>
  <keyword>Duration of treatment</keyword>
  <keyword>Multidrug resistant bacteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

